Science2 hOctober 7, 2026, 03:36

Epigenetic therapy suppresses hepatitis B in mice for six months

nChroma Bio's CRMA-1001 epigenetically silences HBV DNA without cutting the genome. About 90% of mice given three monthly doses showed no virus for six months, and monkey safety tests found no notable side effects. A Phase 1/2 trial is underway.

Singularity Hub

Open source

Epigenetic therapy suppresses hepatitis B in mice for six months

Three monthly doses of CRMA-1001 suppressed the virus in ~90% of mice for 6 months
A single dose cut viral DNA activity and HBsAg levels more than 1000-fold
Monkey safety tests showed no notable side effects
Phase 1/2 trials began in Hong Kong, authorized in New Zealand and the UK

#NChromaBio

Gene Therapy Restores 'Lost' Memories in Mice by Reprogramming Neurons

Science

Ukraine Sets Six-Month Humanoid Kill Benchmark With Robot That Cannot Work in Rain

Software

Windows 11 26H2: Microsoft grades its six-month reset

Security

Epigenetic therapy suppresses hepatitis B in mice for six months

Gene Therapy Restores 'Lost' Memories in Mice by Reprogramming Neurons

Ukraine Sets Six-Month Humanoid Kill Benchmark With Robot That Cannot Work in Rain

Windows 11 26H2: Microsoft grades its six-month reset

Cisco: 79% of organizations need six months or more to deploy new security controls